Search results
Results from the WOW.Com Content Network
In alloimmunity, the body creates antibodies (called alloantibodies) against the alloantigens, attacking transfused blood, allotransplanted tissue, and even the fetus in some cases. Alloimmune ( isoimmune ) response results in graft rejection , which is manifested as deterioration or complete loss of graft function.
Some disorders, such as systemic lupus erythematosus (SLE) may be more likely if several autoantibodies are present, while others, such as mixed connective tissue disease (MCTD) may be more likely if a single autoantibody, ribonucleic protein (RNP), is the only one present. Those who have more than one autoimmune disorder may have several ...
Isoantibodies, formerly called alloantibodies, are antibodies produced by an individual against isoantigens produced by members of the same species. In the case of the species Homo sapiens, for example, there are a significant number of antigens that are different in every individual. When antigens from another individual are introduced into ...
Subtypes of antinuclear antibodies include anti-Smith and anti-double stranded DNA antibodies (which are linked to SLE) and anti-histone antibodies (which are linked to drug-induced lupus). Anti-dsDNA antibodies are highly specific for SLE; they are present in 70% of cases, whereas they appear in only 0.5% of people without SLE. [13]
Antibody allotypes came back to spotlight due to development and use of therapies based on monoclonal antibodies.These recombinant human glycoproteins and proteins are now well established in clinical practise, but sometimes leads to adverse effects such as generation of antitherapeutic antibodies that negates therapy or even cause severe reactions to the therapy.
In systemic lupus there are autoantibodies to DNA, which cannot evoke a T cell response, and limited evidence for T cell responses implicates nucleoprotein antigens. In Celiac disease there are autoantibodies to tissue transglutaminase but the T cell response is to the foreign protein gliadin.
The classical complement pathway can be initiated by the binding of antigen-antibody complexes to the C1q protein. The globular regions of C1q recognize and bind to the Fc region of antibody isotypes IgG or IgM. [2] These globular regions of C1q can also bind to bacterial and viral surface proteins, apoptotic cells, and acute phase proteins. [5]
Anti-histone antibodies are autoantibodies that are a subset of the anti-nuclear antibody family, which specifically target histone protein subunits or histone complexes. [1] They were first reported by Henry Kunkel , H.R. Holman, and H.R.G. Dreicher in their studies of cellular causes of lupus erythematosus in 1959–60.